deferoxamine has been researched along with Glucose Intolerance in 4 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Glucose Intolerance: A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diabetes mellitus was present in 6." | 2.61 | Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β-Thalassemia Major: A Meta-Analysis. ( Chen, DY; Chen, W; He, LN; Liu, NQ; Lu, D; Sun, XF; Xie, YJ; Xiong, ZY; Yang, Y; Yang, YH, 2019) |
| "Deferiprone was the most effective chelator to improve glucose homeostasis in chronically transfused thalassemics." | 1.48 | Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major. ( Bagmar, S; Dabas, A; Gomber, S; Madhu, SV, 2018) |
| "Risk factors associated with IDDM and IGT were lack of compliance with chelation therapy, iron overload and the presence of cirrhosis and severe fibrosis." | 1.30 | Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients. ( De Sanctis, V; Fortini, M; Gamberini, MR; Gilli, G; Testa, MR, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomber, S | 1 |
| Dabas, A | 1 |
| Bagmar, S | 1 |
| Madhu, SV | 1 |
| He, LN | 1 |
| Chen, W | 1 |
| Yang, Y | 1 |
| Xie, YJ | 1 |
| Xiong, ZY | 1 |
| Chen, DY | 1 |
| Lu, D | 1 |
| Liu, NQ | 1 |
| Yang, YH | 1 |
| Sun, XF | 1 |
| Platis, O | 1 |
| Anagnostopoulos, G | 1 |
| Farmaki, K | 1 |
| Posantzis, M | 1 |
| Gotsis, E | 1 |
| Tolis, G | 1 |
| Gamberini, MR | 1 |
| Fortini, M | 1 |
| Gilli, G | 1 |
| Testa, MR | 1 |
| De Sanctis, V | 1 |
1 review available for deferoxamine and Glucose Intolerance
| Article | Year |
|---|---|
Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β-Thalassemia Major: A Meta-Analysis.
Topics: beta-Thalassemia; Chelation Therapy; Deferoxamine; Diabetes Mellitus; Endocrine System Diseases; Glu | 2019 |
1 trial available for deferoxamine and Glucose Intolerance
| Article | Year |
|---|---|
Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Thera | 2004 |
2 other studies available for deferoxamine and Glucose Intolerance
| Article | Year |
|---|---|
Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major.
Topics: Adolescent; beta-Thalassemia; Blood Glucose; Chelation Therapy; Child; Child, Preschool; Deferiprone | 2018 |
Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelating Agents; Child; Deferoxamine; Diabetes Mellitus, Type | 1998 |